I received this from the company after asking the same questions. It appears the rumer is true. eom
Dear Mr. …………………..
Thank you for your enquiry: In view of the unexpected increase in market activity and the number of enquiries we have received this week we are replying formally with the authority of and on behalf of Amy Scopes and confirm that Mrs Scopes will issue a comprehensive press release shortly.
Information recently released to shareholders and in the public domain that may have led to speculation have included:
1. The current status of the company’s IP and confirmation that all annuities are up to date.
2. That in the US we have been in negotiation for the use of the technology, to implement a system and use the licensed product (the bottle) in a packaging company start up; that this may result in a JV or similar if in the interest of the shareholders and we are part of the negotiation for regional funding.
3. That in EU we are preparing the user requirement specification and technical specification for a clinical trial supplies application to administer oral solution.
4. That there was a re-organisation of the company structure imminent
5. That the current sales and marketing activity of the company has been considerable and funded without debt or outside equity funding.
6. It has been confirmed that Traxxec has not sold any stock
Due to the above and the benefits and security provided by the use of RFID and our expertise and knowledge in the pharmaceutical industry in particular, negotiations outlined in previous correspondence with shareholders have led us to the acquisition of Stem Cell Assurance operating in the emerging stem cell market. This aligns with the current global focus on this industry that has been emphasised by President Obama’s recent statement and we are confident that our actions will be in the interest of the shareholder.
Notwithstanding the above, and although this reply to your enquiry is, of necessity, in general terms at this time, the information is delivered to you in good faith and is accurate and reliable but should not be considered as personal investment guidance, for which you should seek appropriate advice.
We trust this is satisfactory at this time and that you will be patient for further news.
ENQUIRIES
Tel: 0845 396 8168
